ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates – Authors reply thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our unique population responds to the Pfizer-BioNTech COVID-19 vaccine. The study, ‘Ka Mātau, Ka Ora' (from knowledge comes wellbeing), is being .
No survival benefit from aspirin in COVID-19 patients
9th June 2021
Findings of the UK RECOVERY trial show that use of aspirin in the hope of reducing blood clotting in patients hospitalised with COVID-19 does not have any impact on survival.
The study assessed whether aspirin could help reduce blood clotting and therefore improve lung function and patient outcomes in severe cases of COVID-19.
The trial involved a cohort of nearly 15,000 hospitalised COVID-19 patients, of which 7,351 were randomised to receive 150mg aspirin once daily and 7,541 patients standard care alone.
The researchers found no evidence that aspirin treatment reduced mortality in hospitalised patients with COVID-19, with no significant difference in the primary endpoint of 28-day mortality (17% aspirin vs. 17% usual care).